COMP <GO>
ISRG vs EW // GROSS PROFIT MARGIN
Intuitive Surgical Inc. (NASDAQ) VS. Edwards Lifesciences Corporation (NYSE) • 15-METRIC TALLY: ISRG 8
— EW 5
▲ GROSS PROFIT MARGIN LEADER: EW
LAST: $436.87 (+1.13%) • MKT CAP: $149.75B
gross-margins
66.00%
LAST: $93.26 (+1.36%) • MKT CAP: $53.03B
gross-margins
78.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ISRG VS. EW)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ISRG | EW | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 66.00% | 78.00% | -12.00 | EW | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 15.00% | 12.50% | +2.50 | ISRG | /roic <GO> |
| EV/EBITDA & P/E Valuation | 46.0x | 35.1x | +10.90 | EW | /valuation <GO> |
| Free Cash Flow Yield | 1.66% | 2.45% | -0.79 | EW | /fcf-yield <GO> |
| Operating Margin | 29.30% | 20.80% | +8.50 | ISRG | /operating-margins <GO> |
| Net Profit Margin | 28.40% | 17.70% | +10.70 | ISRG | /net-margins <GO> |
| Revenue Growth (YoY) | 20.50% | 11.50% | +9.00 | ISRG | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 12.36 | +13.64 | ISRG | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 8/9 | +1.00 | ISRG | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 51.8 | 56.5 | -4.70 | EW | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.97 | 1.08 | -0.11 | EW | /macro-sensitivity <GO> |
| Forward P/E Multiple | 45.8x | 47.2x | -1.40 | ISRG | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $149.75B | $53.03B | $96.72B | ISRG | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ISRG REV | EW REV | ISRG GROSS % | EW GROSS % | ISRG FCF | EW FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $10.06B | $6.07B | 66.0% | 78.0% | $2.58B | $1.33B |
| FY 2024 | $8.35B | $5.44B | 67.5% | 79.5% | $2.04B | $289.9M |
| FY 2023 | $7.12B | $5.01B | — | — | $1.49B | $670.4M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ISRG // BETA 0.97
EW // BETA 1.08